Syros Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

Syros Pharmaceuticals

05/11/2021 13:35

* Syros Pharmaceuticals Inc  SYRS.OQ  reported a quarterly
adjusted loss of 41 cents​​ per share for the quarter ended in
September. The mean expectation of eight analysts for the
quarter was for a loss of 44 cents per share.
* Revenue rose 48.8% to $5.70 million from a year ago;  analysts
expected $4.49 million. 
* The mean earnings estimate of analysts had fallen by
about 0.6% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Syros Pharmaceuticals Inc shares had fallen by 1.1% this
quarter and lost 59.3% so far this year.
* The company reported a quarterly loss of $26.03 million.
* Wall Street's median 12-month price target for Syros
Pharmaceuticals Inc is $19.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated November 5 at 01:35 p.m.
 ​All figures in US dollars unless otherwise stated